Related Experiment Videos
Ifosfamide in small cell lung cancer.
1Department of Medicine, Indiana University, Indianapolis.
Seminars in Oncology
|February 1, 1989
Summary
Ifosfamide shows promise as a chemotherapy agent for small cell lung cancer (SCLC), particularly in combination regimens. Further studies are evaluating its efficacy as a first-line treatment for extensive SCLC.
Area of Science:
- Oncology
- Pharmacology
Background:
- Ifosfamide, a cyclophosphamide analogue, is effective in various cancers.
- Ifosfamide exhibits less myelosuppression than cyclophosphamide, making it suitable for combination chemotherapy.
Purpose of the Study:
- To evaluate single-agent ifosfamide in small cell lung cancer (SCLC).
- To assess the efficacy of ifosfamide in combination chemotherapy for extensive SCLC.
Main Methods:
- Review of existing studies on single-agent ifosfamide in SCLC.
- Ongoing clinical trials evaluating cisplatin/carboplatin plus etoposide plus ifosfamide regimens.
- A Hoosier Oncology Group (HOG) study comparing a three-drug regimen (cisplatin plus etoposide plus ifosfamide) against a two-drug regimen (cisplatin plus etoposide).
Main Results:
- Single-agent ifosfamide demonstrates comparable activity to other agents in previously treated SCLC patients.
- Combination chemotherapy regimens including ifosfamide are under investigation globally.
Conclusions:
- Ifosfamide is a viable option for SCLC treatment.
- The HOG study aims to determine if ifosfamide improves outcomes in first-line extensive SCLC therapy.